Viracta Therapeutics to Present at Upcoming Investor Conferences

Rhea-AI Summary

Viracta Therapeutics (NASDAQ: VIRX) is set to present at multiple investor conferences in November 2021. Key events include:

• Credit Suisse 30th Annual Healthcare Conference: Nov 8-12, Presentation on Nov 11 at 1:50 PM ET.
• Jefferies London Healthcare Conference: Nov 16-17, Presentation on Nov 17 at 10:40 AM GMT.
• Piper Sandler 33rd Annual Healthcare Conference: Nov 29-Dec 2, Presentation on Nov 22.
• Evercore ISI 4th Annual HealthCONx Conference: Nov 29-Dec 2, Presentation on Dec 2 at 3:55 PM ET.

Webcasts will be available on their website.

SAN DIEGO, Nov. 1, 2021 /PRNewswire/ -- Viracta Therapeutics, Inc. (NASDAQ: VIRX), a precision oncology company targeting virus-associated malignancies, today announced that company management is scheduled to present and host one-on-one meetings at the following upcoming investor conferences:

Credit Suisse 30th Annual Healthcare Conference (virtual)
Conference Dates:	November 8 – 12, 2021
Presentation Date:	November 11, 2021
Presentation Time:	1:50 PM ET
Format:	Corporate presentation

 

Jefferies London Healthcare Conference (in-person)
Conference Dates:	November 16 – 17, 2021
Presentation Date:	November 17, 2021
Presentation Time:	10:40 AM GMT/ 5:40 AM ET
Format:	Corporate presentation

 

Piper Sandler 33rd Annual Healthcare Conference (virtual)
Conference Dates:	November 29 – December 2, 2021
Presentation Available:	November 22, 2021, at 10:00 AM ET
Format:	Corporate presentation

 

Evercore ISI 4th Annual HealthCONx Conference (virtual)
Conference Dates:		November 29 – December 2, 2021
Presentation Date:		December 2, 2021
Presentation Time:		3:55 PM ET
Format:		Fireside chat

A live webcast of each of the presentations will be available under "Events and Webcasts" in the Investors section of the Viracta website at https://viracta.investorroom.com/events-and-webcasts.  Replays of each webcast will be archived on the Viracta website for at least 30 days following the presentation.

About Viracta Therapeutics, Inc.

Viracta is a precision oncology company targeting virus-associated malignancies. Viracta's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in two Phase 2 clinical trials for EBV-positive (EBV⁺) lymphoma and one Phase 1b/2 trial in patients with EBV⁺ nasopharyngeal carcinoma and other EBV⁺ solid tumors. Viracta is also pursuing the application of its inducible synthetic lethality approach in other virus-related cancers. For additional information please visit www.viracta.com.

Investor Relations Contact:

Ashleigh Barreto
Head of Investor Relations and Corporate Communications
Viracta Therapeutics, Inc.
abarreto@viracta.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/viracta-therapeutics-to-present-at-upcoming-investor-conferences-301413256.html

SOURCE Viracta

FAQ

What conferences will Viracta Therapeutics present at in November 2021?

Viracta Therapeutics will present at the Credit Suisse 30th Annual Healthcare Conference, Jefferies London Healthcare Conference, Piper Sandler 33rd Annual Healthcare Conference, and Evercore ISI 4th Annual HealthCONx Conference.

What is Viracta's presentation schedule during the Credit Suisse conference?

Viracta will present on November 11, 2021, at 1:50 PM ET during the Credit Suisse 30th Annual Healthcare Conference.

When will Viracta present at the Jefferies London Healthcare Conference?

Viracta will present on November 17, 2021, at 10:40 AM GMT during the Jefferies London Healthcare Conference.

When will the webcasts of Viracta's presentations be available?

Webcasts of Viracta's presentations will be available on their website shortly after each event and will be archived for at least 30 days.

What is the focus of Viracta Therapeutics?

Viracta Therapeutics focuses on precision oncology, specifically targeting virus-associated malignancies.